<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953418</url>
  </required_header>
  <id_info>
    <org_study_id>COVB3050540</org_study_id>
    <nct_id>NCT02953418</nct_id>
  </id_info>
  <brief_title>RFA for Flat Type High-grade and Medium-grade Intraepithelial Squamous Neoplasia</brief_title>
  <acronym>REACH</acronym>
  <official_title>A Multicenter Trial of Endoscopic Radiofrequency Ablation for High-grade and Low-grade Intraepithelial Squamous Neoplasia Using the Barrx™ Flex Radiofrequency Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, prospective cohort clinical trial in greater China&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment taking longer than expected.&#xD;
  </why_stopped>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Actual">July 20, 2019</completion_date>
  <primary_completion_date type="Actual">July 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Complete Response (CR)</measure>
    <time_frame>12 month</time_frame>
    <description>The primary endpoint is the percentage of subjects with &quot;complete response (CR)&quot;, defined as complete eradication of squamous histological abnormalities (MGIN or worse) within the treatment area (TA) at 12 months after the initial treatment session</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response at Three Months</measure>
    <time_frame>3 Months</time_frame>
    <description>Number of patients with a CR after primary RFA, defined as absence of MGIN or worse in any of the biopsies from the treatment area at the three months visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Within the Treatment Area</measure>
    <time_frame>3, 6 and 12 Month</time_frame>
    <description>Number of patients demonstrating complete response within the treatment area (TA), defined as detection of ESCC in biopsy or resection specimen at any time within the first 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Progression Outside the Treatment Area</measure>
    <time_frame>Initial, 3, 6, 9 and 12 month</time_frame>
    <description>Proportion of patients demonstrating MGIN or worse outside the TA during treatment phase or follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Esophageal Squamous Cell Neoplasia (ESCN)</condition>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>RFA</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <other_name>The Barrx™ Flex Radiofrequency Ablation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is 18-85 years of age&#xD;
&#xD;
          2. Patient has evidence of ESCN, within the last 3 months, patient demonstrated a new&#xD;
             diagnosis or a reconfirmed diagnosis of squamous MGIN and/or HGIN of the esophagus&#xD;
&#xD;
          3. On endoscopic examination, subject has at least one USL that measures at least 3 cm in&#xD;
             at least one dimension and greater than ¼ of the esophageal circumference and has MGIN&#xD;
             or HGIN on biopsy, confirmed by central pathologist&#xD;
&#xD;
          4. All lesions in the esophagus are completely flat (Paris type 0-IIb), both on WLE and&#xD;
             Lugol's chromoendoscopy&#xD;
&#xD;
          5. The maximum allowable linear length of &quot;USL-bearing esophagus&quot; is 12 cm&#xD;
&#xD;
          6. Baseline endoscopic ultrasound (EUS) (if applicable) shows no exclusionary findings&#xD;
             for the trial&#xD;
&#xD;
          7. Computed Tomography )CT( scan of chest and upper third of the abdomen (if applicable)&#xD;
             shows no exclusionary findings for the trial&#xD;
&#xD;
          8. Based on the judgment of the study endoscopist, the patient is eligible for treatment,&#xD;
             follow-up endoscopy, and biopsy as required by the protocol&#xD;
&#xD;
          9. EMR or ESD occurred &gt; 3 months before enrollment, patients may be eligible for the&#xD;
             study if procedure was curative (negative margins and no risk of lymph node&#xD;
             involvement) and the patient has no other findings concerning for cancer&#xD;
&#xD;
         10. The subject is willing to provide written, informed consent to participate in this&#xD;
             clinical study and understands the responsibilities of trial participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has esophageal squamous cell carcinoma (ESCC)&#xD;
&#xD;
          2. Any non-flat (Paris type 0-I, 0-IIa, 0-IIc, 0-III) abnormalities anywhere in the&#xD;
             esophagus&#xD;
&#xD;
          3. Any abnormalities under WLE, Lugol's chromoendoscopy or NBI that are suspicious for&#xD;
             ESCC anywhere in the esophagus (e.g. 'pink sign' USL, defined as a color change after&#xD;
             Lugol's staining: initially whitish yellow and pink 2-3 minutes later)&#xD;
&#xD;
          4. Any USL with MGIN or worse on biopsy outside the treatment area&#xD;
&#xD;
          5. Esophageal stricture preventing passage of a therapeutic endoscope&#xD;
&#xD;
          6. Prior endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)&#xD;
             which occurred &lt; 3 months before enrollment&#xD;
&#xD;
          7. Any esophageal dilation in the past 12 months&#xD;
&#xD;
          8. Any history of a non-squamous cell cancer of the esophagus, or any history of a&#xD;
             squamous cell cancer of the esophagus (any stage)&#xD;
&#xD;
          9. Any previous ablative therapy within the esophagus (photodynamic therapy, multipolar&#xD;
             electrical coagulation, argon plasma coagulation, laser treatment, or other) or any&#xD;
             radiation therapy to the esophagus&#xD;
&#xD;
         10. Previous esophageal surgery, except fundoplication without complications (i.e., no&#xD;
             slippage, dysphagia, etc.)&#xD;
&#xD;
         11. Evidence of esophageal varices detected within last 6 months or at initial RFA&#xD;
             procedure&#xD;
&#xD;
         12. Patient has active reflux esophagitis grade C or D&#xD;
&#xD;
         13. Evidence of eosinophilic esophagitis on endoscopy and/or histology&#xD;
&#xD;
         14. Inner diameter of the esophagus measuring &lt;18 mm&#xD;
&#xD;
         15. Report of uncontrolled coagulopathy with international normalized ratio (INR) &gt; 2 or&#xD;
             platelet count &lt;75,000 platelets per µL (note: a complete blood count is not required&#xD;
             for all subjects in this study)&#xD;
&#xD;
         16. Patient is using anti-thrombotic agents that cannot be discontinued 7 days before and&#xD;
             after therapeutic sessions&#xD;
&#xD;
         17. Patient has an implantable pacing device (examples: automated implantable cardioverter&#xD;
             defibrillator, neurostimulator, cardiac pacemaker) and has not received clearance for&#xD;
             enrollment in this study by specialist responsible for the pacing device&#xD;
&#xD;
         18. Patient has life expectancy less than 5 years&#xD;
&#xD;
         19. Patient suffers from psychiatric or other illness and/or has a known history of&#xD;
             unresolved drug or alcohol dependency that would limit ability to comprehend or follow&#xD;
             instructions related to informed consent, post- treatment instructions, or follow-up&#xD;
             guidelines&#xD;
&#xD;
         20. Patient is considered to be part of a vulnerable population (e.g. prisoners or those&#xD;
             without sufficient mental capacity)&#xD;
&#xD;
         21. The subject has participated in an investigational drug or device research study&#xD;
             within 30 days of enrollment that would interfere with this study&#xD;
&#xD;
         22. Patient is pregnant or has plans to become pregnant in the ensuing 12 months&#xD;
             (confirmation of non-pregnant status in women of child-bearing age and ability&#xD;
             required with urine or blood test to be eligible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Cafaro, RN</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic Gastrointestinal &amp; Hepatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <results_first_submitted>July 16, 2020</results_first_submitted>
  <results_first_submitted_qc>July 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02953418/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02953418/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Radiofrequency Ablation</title>
          <description>Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.&#xD;
Radiofrequency ablation: RFA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Radiofrequency Ablation</title>
          <description>Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.&#xD;
Radiofrequency ablation: RFA</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.41" spread="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.88" spread="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.93" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Complete Response (CR)</title>
        <description>The primary endpoint is the percentage of subjects with &quot;complete response (CR)&quot;, defined as complete eradication of squamous histological abnormalities (MGIN or worse) within the treatment area (TA) at 12 months after the initial treatment session</description>
        <time_frame>12 month</time_frame>
        <population>As the study was terminated early, only 8 subjects completed 12 month follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency Ablation</title>
            <description>Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.&#xD;
Radiofrequency ablation: RFA</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Complete Response (CR)</title>
          <description>The primary endpoint is the percentage of subjects with &quot;complete response (CR)&quot;, defined as complete eradication of squamous histological abnormalities (MGIN or worse) within the treatment area (TA) at 12 months after the initial treatment session</description>
          <population>As the study was terminated early, only 8 subjects completed 12 month follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response at Three Months</title>
        <description>Number of patients with a CR after primary RFA, defined as absence of MGIN or worse in any of the biopsies from the treatment area at the three months visit</description>
        <time_frame>3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency Ablation</title>
            <description>Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.&#xD;
Radiofrequency ablation: RFA</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response at Three Months</title>
          <description>Number of patients with a CR after primary RFA, defined as absence of MGIN or worse in any of the biopsies from the treatment area at the three months visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Within the Treatment Area</title>
        <description>Number of patients demonstrating complete response within the treatment area (TA), defined as detection of ESCC in biopsy or resection specimen at any time within the first 12 months.</description>
        <time_frame>3, 6 and 12 Month</time_frame>
        <population>Not all patients in the study were followed for the duration of the treatment phase of 12 months due to study termination. Therefore, primary and secondary endpoint data sample size may vary based on how many visits each subject completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency Ablation</title>
            <description>Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.&#xD;
Radiofrequency ablation: RFA</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Within the Treatment Area</title>
          <description>Number of patients demonstrating complete response within the treatment area (TA), defined as detection of ESCC in biopsy or resection specimen at any time within the first 12 months.</description>
          <population>Not all patients in the study were followed for the duration of the treatment phase of 12 months due to study termination. Therefore, primary and secondary endpoint data sample size may vary based on how many visits each subject completed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Month Complete Response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Complete Response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Complete Response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Progression Outside the Treatment Area</title>
        <description>Proportion of patients demonstrating MGIN or worse outside the TA during treatment phase or follow-up</description>
        <time_frame>Initial, 3, 6, 9 and 12 month</time_frame>
        <population>Not all patients in the study were followed for the duration of the treatment phase of 12 months due to study termination. Therefore, primary and secondary endpoint data sample size may vary based on how many visits each subject completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency Ablation</title>
            <description>Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.&#xD;
Radiofrequency ablation: RFA</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression Outside the Treatment Area</title>
          <description>Proportion of patients demonstrating MGIN or worse outside the TA during treatment phase or follow-up</description>
          <population>Not all patients in the study were followed for the duration of the treatment phase of 12 months due to study termination. Therefore, primary and secondary endpoint data sample size may vary based on how many visits each subject completed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary RFA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9-Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety data was evaluated throughout the entirety of follow up, after the study was terminated safety was evaluated for 90 days post RFA procedure.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Radiofrequency Ablation</title>
          <description>Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.&#xD;
Radiofrequency ablation: RFA</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>H1N1Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma of the hypopharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution and Investigator shall not publish the Study results until after Medtronic's multi-site publication or until the elapse of 12 months from the close of the study at all Study sites, whichever occurs earlier.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early, therefore there was a limited data set for analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Clinical Affairs</name_or_title>
      <organization>Medtronic MITG-RGI</organization>
      <phone>303-882-6759</phone>
      <email>Tumordirectedtherapiesclinical@Medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

